LDLR and hypertriglyceridemia: Because human APOE2 homozygous hypertriglyceridemia patients lack the ability to efficiently clear TRLs through the LDLR/LRP1 axis, our results suggest that volanesorsen can reduce plasma TG levels independent of this apoE-driven hepatic TRL clearance pathway.